Tag Archives: OMED

Best Low Price Stocks To Watch Right Now

Peyto (OTCPK:PEYUF) is a Canadian E&P company whose production profile is dominated by dry gas (92%). With the low price of natural gas, it has been a tough couple of years for Peyto’s shareholders. That said, the company has maintained its dividend payout through the commodity price downturn. Recently natural gas prices have recovered from their lows, but Peyto’s stock has not kept pace. In fact, it’s gone the other direction:

Click to enlarge

As the chart above show, the stock is down ~13% over the past three months as natural gas – as measure by both the Henry Hub and AECO indexes – has rallied sharply with significant winter withdrawals and forecasts that additional cold weather is on the way:

Best Low Price Stocks To Watch Right Now: Sempra Energy(SRE)

Advisors’ Opinion:

  • [By Shanthi Rexaline]

    Giving six reasons for Sempra Energy (NYSE: SRE)’s above-peer-average growth, Argus said it is reiterating its Hold rating on the shares of the company, while it is also maintaining its long-term Buy rating.

  • [By Lisa Levin]

    Sempra Energy (NYSE: SRE) announced plans to acquire Oncor for $9.45 billion in cash.

    Sempra Energy projects the deal to complete in the first half of 2018.

  • [By David Dittman]

    PG&E Corp (NYSE: PCG), Edison International (NYSE: EIX) and Sempra Energy (NYSE: SRE) are the parent entities of California’s investor-owned utilities.

  • [By Lisa Levin]

    In trading on Friday, utilities shares fell by 0.93 percent. Meanwhile, top losers in the sector included Sempra Energy (NYSE: SRE), down 3 percent, and CenterPoint Energy, Inc. (NYSE: CNP), down 3 percent.

  • [By WWW.THESTREET.COM]

    The upgrade comes after Berkshire’s deal with Energy Future Holdings Corp to acquire its Oncor Electric Delivery interest was terminated Monday. Sempra Energy (SRE) agreed to buy Oncor for $9.45 billion, besting Berkshire’s $9 billion offer.

Best Low Price Stocks To Watch Right Now: Heico Corporation(HEI)

Advisors’ Opinion:

  • [By Monica Gerson]

    Heico Corp (NYSE: HEI) is estimated to post its quarterly earnings at $0.54 per share.

    Exa Corp (NASDAQ: EXA) is projected to post a quarterly loss at $0.08 per share on revenue of $16.68 million.

  • [By Shauna O’Brien]

    Heico Corp (HEI) announced on Thursday that it has agreed to purchase Lucix Corp, a manufacturer of military satellite, airborne, and ground systems.

    The terms of the deal were not disclosed, but HEI revealed that the acquisition could be completed within 60 days. The deal is expected to impact HEI’s earnings within the first year.

    Heico shares were up 67 cents, or 1.04%, during Thursday morning trading. The stock is up 46% YTD.

Best Low Price Stocks To Watch Right Now: OncoMed Pharmaceuticals, Inc.(OMED)

Advisors’ Opinion:

  • [By Paul Ausick]

    OncoMed Pharmaceuticals Inc. (NASDAQ: OMED) dropped nearly 44% Monday to post a new 52-week low of $4.94 after closing Friday at $8.76. The stock’s 52-week high is $15.49. Volume of about 3.3 million shares was nearly 20 times the daily average of around 182,000. A proposed deal with Bayer AG fell through and one of the company’s drugs failed a phase 2 clinical trial.

  • [By Teresa Rivas]

    OncoMed Pharmaceuticals (OMED) has lost more than a third of its value Monday, after Bayer decided not to exercise its option to license the firms Phase II-ready WNT pathway inhibitors Vantictumab and Ipafricept, which treat pancreatic cancer.

    Pixabay

    That wasnt the only bad news, however, as the firms randomized-controlled Phase II “YOSEMITE” trial of pancreatic cancer drug demcizumab also missed its primary endpoint.

    Leerinks Michael Schmidt and his team reiterated a Market Perform rating on the stock Monday, and lowered their price target from $10 to $6 on the news, calling it a “double setback” for OncoMed.

    More detail from the note:

    This is a major setback for OMED and in our view for the cancer stem cell targets more broadly, which have been a difficult area of drug development. We’ve been cautious on the probability-of-success of these agents and see more promise on OMED’s recent efforts in building a second area of focus in immuno-oncology. Going forward, OMED plans to review and prioritize its R&D pipeline after results from the still pending tarextumab Phase II “PINNACLE” trial in small cell lung cancer (SCLC) and data from the demcizumab “DENALI” trial in NSCLC are available in 2Q17. We remain MP rated in light of the uncertainties around OMED’s pipeline and strategy at this point. We previously assigned a 30% probability of success (POS) to demcizumab which we now have removed from our model. We also think chances that CELG will opt-into this program are slim and we have removed associated POS-adjusted milestone payments from our model. OMED has cash to run operations through 3Q18.

    OncoMed is down 36.1% to $5.60 this afternoon.

  • [By Paul Ausick]

    OncoMed Pharmaceuticals Inc. (NASDAQ: OMED) dropped about 5.3% Wednesday to post a new 52-week low of $4.69 after closing at $4.95 on Tuesday. The stock’s 52-week high is $15.49. Volume was more than double the daily average of around 270,000 shares. The company had no specific news Wednesday.

Hot Clean Energy Stocks To Watch Right Now

William Patalon III

One of my favorite management maxims says to “lead, follow or get out of the way.”

Ford Motor Co. (NYSE: F) just took that maxim to heart – on Monday replacing CEO Mark Fields with insider James Hackett.

I love this move.

We first gave you the lowdown on Hackett’s very alluring track record and skill set a bit more than a year ago in the special briefing “With This One Hire, Ford Just Took the Lead in the ‘Car-of-the-Future’ Race.”

Hackett had been serving on Ford’s board of directors when Fields brought him on board to launch – and build – Ford Smart Mobility LLC, essentially an in-house incubator created to make sure the company stayed relevant in a future dominated by ridesharing, driverless autos and other “mobility” services.

We loved the move at the time. And Hackett didn’t lollygag: Ford was soon making investments in transportation-tech startups, ramping up its experimentation and even announcing a deal to invest $1 billion over the next five years in a new driverless-car venture called Argo AI.

Hot Clean Energy Stocks To Watch Right Now: National Oilwell Varco, Inc.(NOV)

Advisors’ Opinion:

  • [By Tony Daltorio]

    But the best investment in this sector, according to Moors, is National Oilwell Varco Inc. (NYSE: NOV).

    He calls it the “one company that stands to benefit most directly from what is happening in the equipment sector.”

  • [By Shauna O’Brien]

    Jefferies reported on Monday that it has lifted its price target on National-Oilwell Varco, Inc. (NOV).

    The firm has reaffirmed a “Buy” rating on NOV, and has raised the company’s price target from $84 to $91. This price target suggests a 14% increase from the stock’s current price of $78.24.

    Analyst Brad Handler noted that NOV’s weak margin will likely rebound in 2014 and the chances of a dividend increase are high.

    Looking forward, the firm has lifted its order estimates for FY2013 from $10.8 billion to $11.3 billion. FY2014 earnings estimates have been raised from $6.40 to $6.50 per share and FY2015 estimates have been increased from $7.65 to $7.95 per share.

    National-Oilwell Varco shares were up 76 cents, or 0.97% during pre-market trading Monday. The stock is up 14% YTD.

  • [By Jim Robertson]

    On Tuesday, our Elite Opportunity Pronewsletter suggestedgoing long on large cap oilfield equipment manufacturer and technology stock National-Oilwell Varco, Inc (NYSE: NOV):

  • [By Lauren Pollock]

    Among the companies with shares expected to actively trade in Tuesday’s session are Applied Materials Inc.(AMAT), Red Hat Inc.(RHT) and National Oilwell Varco Inc.(NOV)

Hot Clean Energy Stocks To Watch Right Now: OncoMed Pharmaceuticals, Inc.(OMED)

Advisors’ Opinion:

  • [By Paul Ausick]

    OncoMed Pharmaceuticals Inc. (NASDAQ: OMED) dropped about 5.3% Wednesday to post a new 52-week low of $4.69 after closing at $4.95 on Tuesday. The stock’s 52-week high is $15.49. Volume was more than double the daily average of around 270,000 shares. The company had no specific news Wednesday.

  • [By Paul Ausick]

    OncoMed Pharmaceuticals Inc. (NASDAQ: OMED) dropped nearly 44% Monday to post a new 52-week low of $4.94 after closing Friday at $8.76. The stock’s 52-week high is $15.49. Volume of about 3.3 million shares was nearly 20 times the daily average of around 182,000. A proposed deal with Bayer AG fell through and one of the company’s drugs failed a phase 2 clinical trial.

  • [By Teresa Rivas]

    OncoMed Pharmaceuticals (OMED) has lost more than a third of its value Monday, after Bayer decided not to exercise its option to license the firms Phase II-ready WNT pathway inhibitors Vantictumab and Ipafricept, which treat pancreatic cancer.

    Pixabay

    That wasnt the only bad news, however, as the firms randomized-controlled Phase II “YOSEMITE” trial of pancreatic cancer drug demcizumab also missed its primary endpoint.

    Leerinks Michael Schmidt and his team reiterated a Market Perform rating on the stock Monday, and lowered their price target from $10 to $6 on the news, calling it a “double setback” for OncoMed.

    More detail from the note:

    This is a major setback for OMED and in our view for the cancer stem cell targets more broadly, which have been a difficult area of drug development. We’ve been cautious on the probability-of-success of these agents and see more promise on OMED’s recent efforts in building a second area of focus in immuno-oncology. Going forward, OMED plans to review and prioritize its R&D pipeline after results from the still pending tarextumab Phase II “PINNACLE” trial in small cell lung cancer (SCLC) and data from the demcizumab “DENALI” trial in NSCLC are available in 2Q17. We remain MP rated in light of the uncertainties around OMED’s pipeline and strategy at this point. We previously assigned a 30% probability of success (POS) to demcizumab which we now have removed from our model. We also think chances that CELG will opt-into this program are slim and we have removed associated POS-adjusted milestone payments from our model. OMED has cash to run operations through 3Q18.

    OncoMed is down 36.1% to $5.60 this afternoon.

Hot Clean Energy Stocks To Watch Right Now: Broadcom Corporation(BRCM)

Advisors’ Opinion:

  • [By Shauna O’Brien]

    Susquehanna reported on Tuesday that it has raised its rating on Broadcom Corporation (BRCM).

    The firm has upgraded BRCM from “Neutral” to “Positive,” and has lifted the company’s price target from $33 to $35. This price target suggests a 23% upside from the stock’s current price of $26.91.

    Analyst Chris Caso commented: “Our downgrade of BRCM in May was predicated on already high Street expectations on handsets and no notable improvement in networking to drive upside. We think expectations and the stock price have now been sufficiently reset ahead of what we expect to be catalysts in 2014 including the iPhone 6 product cycle, potential improvement in networking and the impact from the recent Renesas acquisition. In addition, after several years of overspending on their handset initiatives, we think we are now closer to the point where the company either captures a return on that investment or is forced to moderate spending either of which benefit profitability. We see the upcoming December analyst meeting as a potential intermediate catalyst.”

    Broadcom shares were up 38 cents, or 1.41%, during pre-market trading Tuesday. The stock is down 19% YTD.

recommended stocks to buy

After a rally for the ages, the price of oil is back over $50. But the biggest threat to oil might be more production from exploration & production companies drilling in the U.S. shale, say Credit Suisse analyst Mark Lear and team, who cut their ratings on Carrizo Oil & Gas (CRZO), Laredo Petroleum (LPI) and Sanchez Energy (SN). They explain why:

Agence France-Presse/Getty Images

A clear benefit of the price cycle has been the vastly improved efficiency and productivity of shale. Operators have learned to make do with less, cash flow as well as rigs, and have taken advantage of lower costs to improve productivity, drilling faster and increasing completion intensity. We remain confident that shale will remain an integral part of global crude supply, but show in our commodities team note…that shale may ultimately be too productive as WTI approaches $70/bbl. As a result, we have taken our long-term WTI forecast from $67.50/bbl to $62.50. Operators at the low end of the cost curve in particular would benefit from crude remaining more range bound as returns at current prices justify development and less activity in higher cost basins would likely push out pending cost inflation.

recommended stocks to buy: OncoMed Pharmaceuticals, Inc.(OMED)

Advisors’ Opinion:

  • [By Paul Ausick]

    OncoMed Pharmaceuticals Inc. (NASDAQ: OMED) dropped about 5.3% Wednesday to post a new 52-week low of $4.69 after closing at $4.95 on Tuesday. The stock’s 52-week high is $15.49. Volume was more than double the daily average of around 270,000 shares. The company had no specific news Wednesday.

  • [By Teresa Rivas]

    OncoMed Pharmaceuticals (OMED) has lost more than a third of its value Monday, after Bayer decided not to exercise its option to license the firms Phase II-ready WNT pathway inhibitors Vantictumab and Ipafricept, which treat pancreatic cancer.

    Pixabay

    That wasnt the only bad news, however, as the firms randomized-controlled Phase II “YOSEMITE” trial of pancreatic cancer drug demcizumab also missed its primary endpoint.

    Leerinks Michael Schmidt and his team reiterated a Market Perform rating on the stock Monday, and lowered their price target from $10 to $6 on the news, calling it a “double setback” for OncoMed.

    More detail from the note:

    This is a major setback for OMED and in our view for the cancer stem cell targets more broadly, which have been a difficult area of drug development. We’ve been cautious on the probability-of-success of these agents and see more promise on OMED’s recent efforts in building a second area of focus in immuno-oncology. Going forward, OMED plans to review and prioritize its R&D pipeline after results from the still pending tarextumab Phase II “PINNACLE” trial in small cell lung cancer (SCLC) and data from the demcizumab “DENALI” trial in NSCLC are available in 2Q17. We remain MP rated in light of the uncertainties around OMED’s pipeline and strategy at this point. We previously assigned a 30% probability of success (POS) to demcizumab which we now have removed from our model. We also think chances that CELG will opt-into this program are slim and we have removed associated POS-adjusted milestone payments from our model. OMED has cash to run operations through 3Q18.

    OncoMed is down 36.1% to $5.60 this afternoon.

  • [By Paul Ausick]

    OncoMed Pharmaceuticals Inc. (NASDAQ: OMED) dropped nearly 44% Monday to post a new 52-week low of $4.94 after closing Friday at $8.76. The stock’s 52-week high is $15.49. Volume of about 3.3 million shares was nearly 20 times the daily average of around 182,000. A proposed deal with Bayer AG fell through and one of the company’s drugs failed a phase 2 clinical trial.

recommended stocks to buy: Autodesk, Inc.(ADSK)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    For Thursday, watch for Burlington Stores (BURL) and Kroger (KR) , along with AutoDesk (ADSK) and Marvell Technologies (MRVL) . Cramer would be a buyer of all but Kroger, where he’s waiting for the grocery wars to subside.

  • [By Craig Jones]

    CNBC’s Jim Cramer of “Mad Money” said in the segment of the show called “Lightning Round” that Autodesk, Inc. (NASDAQ: ADSK) should be bought. He thinks there is nothing wrong with the stock, and he added that piracy, its biggest problem, is being solved.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Wednesday was Autodesk, Inc. (NASDAQ: ADSK) which traded down about 16% at $109.34. The stocks 52-week range is $68.06 to $130.92. Volume was19.3 million versus the daily average of 1.6 million shares.

  • [By Lisa Levin]

    In trading on Wednesday, technology shares fell 2.51 percent. Meanwhile, top losers in the sector included Autodesk, Inc. (NASDAQ: ADSK), down 15 percent, and Data I/O Corporation (NASDAQ: DAIO) down 13 percent.

recommended stocks to buy: MediWound Ltd.(MDWD)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Mediwound Ltd (NASDAQ: MDWD) were down 17 percent to $5.03. Mediwound priced its 4,400,000 offering of ordinary shares at $5 per share.

    Aldeyra Therapeutics Inc (NASDAQ: ALDX) was down, falling around 20 percent to $7.30. Aldeyra Therapeutics reported proposed public offering of common stock.

recommended stocks to buy: AdvanSix Inc. (ASIX)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on Vodafone Group (VOD) , Schlumberger (SLB) , Encana (ECA) , Arconic (ARNC) and AdvanSix (ASIX) .

    Cramer was bearish on U.S. Silica Holdings (SLCA) .

recommended stocks to buy: Cyclacel Pharmaceuticals Inc.(CYCC)

Advisors’ Opinion:

  • [By Alex McGuire]

    As a service to our readers, the following list provides the 10 top pharmaceutical stocks to watch this month (May 2017), including the biggest gainers from April…

    Pharmaceutical Stock Current Share Price April 2017 Gain
    Cleveland BioLabs Inc. (Nasdaq: CBLI) $3.62 +120.6%
    Nexvet Biopharma Plc. (Nasdaq: NVET) $6.61 +69.7%
    Motif Bio Plc. (Nasdaq ADR: MTFB) $10.10 +68.2%
    Axovant Sciences Ltd. (NYSE: AXON) $24.43 +62.3%
    Cyclacel Pharmaceuticals Inc. (Nasdaq: CYCC) $5.49 +46.7%
    Conatus Pharmaceuticals Inc. (Nasdaq: CNAT) $8.67 +44.9%
    Akebia Therapeutics Inc. (Nasdaq: AKBA) $13.07 +43.3%
    Akorn Inc. (Nasdaq: AKRX) $33.28 +38.9%
    Rockwell Medical Inc. (Nasdaq: RMTI) $8.78 +37.4%
    Akari Therapeutics Plc. (Nasdaq ADR: AKTX) $15.02 +35.4%

    The best-performing pharma stock of the month – Cleveland BioLabs Inc. – surged 120.6% to $3.53 a share by April 28. That crushed both the Nasdaq Biotech Index’s 1.5% gain and the Dow Jones’ 1.3% rise over the same period.

  • [By Alex McGuire]

    These are the 10 best penny stocks that have seen the biggest returns over the last week (March 7 – March 14)…

    Penny StockCurrent PriceWeekly Gain (March 7 – March 14)Ocera Therapeutics Inc. (Nasdaq: OCRX)$1.47+147.1%Internap Corp. (Nasdaq: INAP)$3.28+41.4%Soligenix Inc. (Nasdaq: SNGX)$2.94+40%Navios Maritime Partners LP (NYSE: NMM)$2.63+37%QuickLogic Corp. (Nasdaq: QUIK)$2.14+30.5%Adamis Pharmaceuticals Corp. (Nasdaq: ADMP)$4.60+22.7EXCO Resources Inc. (NYSE: XCO)$0.65+20.5%Cyclacel Pharmaceuticals Inc. (Nasdaq: CYCC)$4.38+20.3%Hebron Technology Co. Ltd. (Nasdaq: HEBT)$3.99+19.1%Curis Inc. (Nasdaq: CRIS)$2.85+18.4%

    As a reminder, this is only a tracking metric of penny stocks trading on SEC-regulated exchanges like the Nasdaq and NYSE. Although these top penny stocks are safer than those trading on the pink sheets, we don’t recommend buying any of them without the proper amount of financial research.

recommended stocks to buy: Emerson Electric Company(EMR)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Bernstein’s Steven Winoker and team contend that Brexit is “bad for all our companies it is just a matter of degree.” They explain why Tyco International (TYC), Idex (IEX), Danaher (DHR),Honeywell International (HON) and Emerson Electric (EMR) could feel some degree of pain:

  • [By Ben Levisohn]

    Lower WACC has moved in lockstep with higher multiples and as the rate regime shifts, we see limited excuses for another leg absent material growth. EPS growth/visibility at a reasonable price will matter, with those that are not reflecting upside today seeing multiple expansion and safety stocks that are not safe reverting. With this backdrop, our top picks are Honeywell, Ingersoll-Rand, and Danaher, with a positive bias on Neutral-rated United Technologies, while we are most negative onGeneral Electric and Rockwell Automation (ROK), with a negative bias on N-rated $51.92 Emerson Electric (EMR)…

  • [By Ben Levisohn]

    3) Other downside catalysts have come and gone, such asEmerson Electric (EMR) effectively ruling out aRockwell deal;

    4) However, our view that the upward trajectory in customer capex spending remains muted combined with the stock still trading at >19x NTM EPS limits our upgrade to just Market-Perform despite our long-term bullish view of industrial automation in general and Rockwell specifically

stocks in the news

Poor Bill Ackman. Shares of Herbalife (HLF), a stock he loves to short, have soared more than 10% today–putting the stock up 40% for the past 12 months–after the multi-level marketer reported better-than-expected earnings last night and said it was close to reaching a settlement over its business practices with the Federal Trade Commission. S&P Global Market Intelligence’s Joe Agnese has the details:

Bloomberg News

We lift our 12-month target by $16 to $72, applying a P/E of 15.2X, in-line with Herbalife’s 5-year average, to our 2016 EPS estimate of $4.75, up from $4.50. We lift our 2017 EPS estimate by $0.26 to $5.20. We see valuation benefiting from moderating regulatory risk and improving volumes, despite weakness in Brazil. An FTC deal may be near, in our view, as Herbalife notes talks are in advanced stages which may result in a monetary payment and injunctive relief. Q1 adjusted EPS of $1.36 vs. $1.29 is $0.29 above our estimate on forex-neutral net sales growth of 11%, above our 5.5% estimate

stocks in the news: Repligen Corporation(RGEN)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Tuesday, our Under the Radar Moversnewsletter suggested going long on small cap bioprocessing stock Repligen Corporation (NASDAQ: RGEN):

    As for Repligen, this one’s a bit more speculative than usual; we’re betting the long-term shape of the chart takes hold, and benefits us in the short run.

stocks in the news: Trina Solar Limited(TSL)

Advisors’ Opinion:

  • [By Elizabeth Balboa]

    The firm has a Sell rating on First Solar, JA Solar Holdings and Trina Solar Limited (ADR) (NYSE: TSL). It maintains a NC rating on SunPower Corporation, Canadian Solar and JinkoSolar Holding.

  • [By Spencer Israel]

    Axiom Capital Managing Director Gordon Johnson upgraded the entire alternative energy sector from Market Underweight to Market Overweight and upgraded SolarCity Corp (NASDAQ: SCTY) from Sell to Hold and Trina Solar Limited (ADR) (NYSE: TSL), Yingli Green Energy Holding Co Ltd (ADR) (NYSE: YGE) and JA Solar Holdings Co., Ltd. (ADR) (NASDAQ: JASO) from Sell to Buy.

  • [By Roberto Pedone]

    Another potential earnings short-squeeze candidate is integrated solar-power products maker Trina Solar (TSL), which is set to release numbers on next Monday before the market open. Wall Street analysts, on average, expect Trina Solar to report revenue of $645.68 million on earnings of 15 cents per share.

    The current short interest as a percentage of the float for Trina Solar is extremely high at 24.5%. That means that out of the 76.94 million shares in the tradable float, 18.88 million shares are sold short by the bears. If the bulls get the earnings news they’re looking for, then shares of TSL could easily rip sharply higher post-earnings as the bears move to cover some of their positions.

    From a technical perspective, TSL is currently trending below both its 50-day and 200-day moving averages, which is bearish. This stock recently formed a double bottom chart pattern at $8.67 to $9.04 a share. Shares of TSL have now started to rebound off those support levels and it’s quickly moving within range of triggering a major breakout trade post-earnings above some key near-term overhead resistance levels.

    If you’re bullish on TSL, then I would wait until after its report and look for long-biased trades if this stock manages to break out above some near-term overhead resistance levels at $10.72 to $11.19 a share and then above its 50-day moving average of $11.17 a share with high volume. Look for volume on that move that hits near or above its three-month average action of 5.17 million shares. If that breakout materializes post-earnings, then TSL will set up to re-test or possibly take out its next major overhead resistance levels at its 200-day moving average of $12.49 to $14 a share, or even $14.50 to $15 a share.

    I would avoid TSL or look for short-biased trades if after earnings it fails to trigger that breakout and then drops back below some near-term support levels at $10 a share to those double bottom support levels at $9.04 to $8

stocks in the news: Fortune Brands Home & Security, Inc.(FBHS)

Advisors’ Opinion:

  • [By Lisa Levin]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Wednesday’s regular session.

stocks in the news: OncoMed Pharmaceuticals, Inc.(OMED)

Advisors’ Opinion:

  • [By Teresa Rivas]

    OncoMed Pharmaceuticals (OMED) has lost more than a third of its value Monday, after Bayer decided not to exercise its option to license the firms Phase II-ready WNT pathway inhibitors Vantictumab and Ipafricept, which treat pancreatic cancer.

    Pixabay

    That wasnt the only bad news, however, as the firms randomized-controlled Phase II “YOSEMITE” trial of pancreatic cancer drug demcizumab also missed its primary endpoint.

    Leerinks Michael Schmidt and his team reiterated a Market Perform rating on the stock Monday, and lowered their price target from $10 to $6 on the news, calling it a “double setback” for OncoMed.

    More detail from the note:

    This is a major setback for OMED and in our view for the cancer stem cell targets more broadly, which have been a difficult area of drug development. We’ve been cautious on the probability-of-success of these agents and see more promise on OMED’s recent efforts in building a second area of focus in immuno-oncology. Going forward, OMED plans to review and prioritize its R&D pipeline after results from the still pending tarextumab Phase II “PINNACLE” trial in small cell lung cancer (SCLC) and data from the demcizumab “DENALI” trial in NSCLC are available in 2Q17. We remain MP rated in light of the uncertainties around OMED’s pipeline and strategy at this point. We previously assigned a 30% probability of success (POS) to demcizumab which we now have removed from our model. We also think chances that CELG will opt-into this program are slim and we have removed associated POS-adjusted milestone payments from our model. OMED has cash to run operations through 3Q18.

    OncoMed is down 36.1% to $5.60 this afternoon.

  • [By Paul Ausick]

    OncoMed Pharmaceuticals Inc. (NASDAQ: OMED) dropped nearly 44% Monday to post a new 52-week low of $4.94 after closing Friday at $8.76. The stock’s 52-week high is $15.49. Volume of about 3.3 million shares was nearly 20 times the daily average of around 182,000. A proposed deal with Bayer AG fell through and one of the company’s drugs failed a phase 2 clinical trial.

  • [By Paul Ausick]

    OncoMed Pharmaceuticals Inc. (NASDAQ: OMED) dropped about 5.3% Wednesday to post a new 52-week low of $4.69 after closing at $4.95 on Tuesday. The stock’s 52-week high is $15.49. Volume was more than double the daily average of around 270,000 shares. The company had no specific news Wednesday.

stocks in the news: J & J Snack Foods Corp.(JJSF)

Advisors’ Opinion:

  • [By Monica Gerson]

    J & J Snack Foods Corp (NASDAQ: JJSF) is estimated to post its quarterly earnings at $0.78 per share on revenue of $231.58 million.

    Nabors Industries Ltd. (NYSE: NBR) is expected to post a quarterly loss at $0.33 per share on revenue of $630.85 million.

Top 10 Gold Stocks To Own Right Now

The S&P 500 and the Dow Jones Industrial Average continued to push higher today, although the Nasdaq was weighed down by a big drops in Netflix (NFLX), which tumbled following earnings today.

European Pressphoto Agency

The S&P 500 gained 0.3% to 2,100.80, while the Dow Jones Industrial Average rose 49.44 points, or 0.3%, to 18,053.60, its highest close since July 20, 2015. The Nasdaq Composite fell 0.4% to 4,940.33.

Netflix tumbled 13% to $94.34 after gaining far fewer overseas subscribers than it had forecast. The Dow Jones Industrial Average was able to offset International Business Machines’ (IBM) 5.7% drop to $143.98 with gains from Goldman Sachs (GS), which gained 2.5% to $162.71, UnitedHealth Group (UNH), which rose 2.1% to $130.50, and Johnson & Johnson (JNJ), which advanced 1.6% to $112.67. IBM was hit by disappointing guidance, while Goldman Sachs shrugged off a low quality beat, Johnson & Johnson lifted guidance, and UnitedHealth easily topped earnings forecasts.

Top 10 Gold Stocks To Own Right Now: Carlsberg A/S (CABGY)

Advisors’ Opinion:

  • [By Mark Fritz]

    Price Target: $124.

    Heineken N.V. (ADR) (OTC: HINKY): Hold.
    Price Target: 82.30 euros.

    Carlsberg A/S (ADR) (OTC: CABGY): Hold.
    Price Target: 652 krones.

    Distillers

Top 10 Gold Stocks To Own Right Now: Atwood Oceanics, Inc.(ATW)

Advisors’ Opinion:

  • [By Matthew DiLallo]

    Shares of Atwood Oceanics (NYSE:ATW) are bounding higher on Wednesday and were up more than 13% by 3:00 p.m. EDT. There wasn’t any news to drive the stock higher today. Instead, it appears that investors finally decided they like the company’s messy fiscal second-quarter report.

  • [By Benzinga News Desk]

    Stephens (Equal-Weight) and Citi (Sell) both downgraded Atwood Oceanics (NYSE: ATW).

    Sell-Side's Most Noteworthy Calls
    Investec downgraded Anheuser-Busch (NYSE: BUD) to Hold.
    Deutsche Bank downgraded Freeport McMoRan (NYSE: FCX) to Hold.
    Goldman Sachs upgraded Microsoft (NASDAQ: MSFT) to Buy.
    Barclays upgraded Teck Resources (NYSE: TCK) to Overweight.
    BTIG started Adobe (NASDAQ: ADBE) at Neutral.
    Deal Talk

    U.S. oil refiner Tesoro (NYSE: TSO) said it would buy Western Refining (NYSE: WNR) for $4.1 billion to add refineries in Texas, New Mexico and Minnesota. The combined company will have refining capacity of over 1.1 million barrels per day. Tesoro has refineries in California, Washington, Alaska, Utah and North Dakota.

  • [By Lee Jackson]

    Atwood Oceanics Inc. (NYSE: ATW) was reiterated with a Hold rating at Jefferies, but the firm raisedits price target on the shares to $13 from $8. That compares with a Wall Street consensus price objective of $8.90. The 52-week trading range for the stock is $4.82 to $15.87. The stock closed Thursday at $13.55.

Top 10 Gold Stocks To Own Right Now: Century Aluminum Company(CENX)

Advisors’ Opinion:

  • [By Craig Jones]

    JPMorgan’s analyst Michael Gambardella downgraded Century Aluminum Co (NASDAQ: CENX) from Overweight to Neutral and reduced its price target from $22 to $14.50, citing alumina cost headwinds as the main reason for the downgrade.

Top 10 Gold Stocks To Own Right Now: SORL Auto Parts Inc.(SORL)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Loxo Oncology Inc (NASDAQ: LOXO) rose 32.7 percent to $65.00 in pre-market trading after the company reported that larotrectinib trial demonstrated 76 percent confirmed objective response rate.
    Dynavax Technologies Corporation (NASDAQ: DVAX) shares rose 22 percent to $7.20 in the pre-market trading session after the company on Friday presented updated data for SD-101 in combination with KEYTRUDA.
    Puma Biotechnology Inc (NASDAQ: PBYI) rose 21.7 percent to $99.75 in pre-market trading as the company disclosed positive PB272 Phase 2 data from TBCRC 022 trial at ASCO17.
    Helios and Matheson Analytics Inc (NASDAQ: HMNY) shares rose 20.7 percent to $3.21 in pre-market trading after the company reported that RedZone has acquired all the assets of Trendit including three technology patents.
    Forestar Group Inc. (NYSE: FOR) rose 13.1 percent to $16.05 in pre-market trading after D.R. Horton, Inc. (NYSE: DHI) proposed to buy 75 percent of Forestar Group for $16.25 per share in cash.
    TG Therapeutics Inc (NASDAQ: TGTX) shares rose 12 percent to $15.50 in pre-market trading after the company said Phase 3 GENUINE trial met primary endpoint with TG-1101 + ibrutinib increasing overall response rate by >70 percent versuss ibrutinib alone.
    Gigamon Inc (NYSE: GIMO) gained 10.8 percent to $43.55. Reuters reported that Gigamon is exploring a potential sale.
    BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) rose 8.7 percent to $6.00 in pre-market trading after the company announced Rapivab pediatric sNDA acceptance by the FDA.
    Array Biopharma Inc (NASDAQ: ARRY) rose 7.2 percent to $8.77 in pre-market trading after gaining 5.68 percent on Friday.
    Ehi Car Services Ltd (ADR) (NYSE: EHIC) shares rose 6.4 percent to $10.76 in pre-market trading. eHi Car Services posted Q1 earnings of $0.06 on sales of $89.43 million.
    Skyworks Solutions Inc (NASDAQ: SWKS) rose 5.9 percent to $114.79 in pre-market trading after gaining 0.69 percent on Friday.
    Sorl Auto
  • [By Lisa Levin]

    Sorl Auto Parts, Inc. (NASDAQ: SORL) was down, falling around 8 percent to $3.68. Greenridge Global downgraded SORL Auto Parts from Buy to Hold.

  • [By ]

    1. Sorl Auto Parts (Nasdaq: SORL)
    Shares of this Chinese automobile brake and safety equipment maker are setting up to be an ideal breakout candidate. Sorl supplies automobile brakes and safety equipment to over 75 original equipment manufacturers, most of them in China.

Top 10 Gold Stocks To Own Right Now: CRB Futures Index(CR)

Advisors’ Opinion:

  • [By Lisa Levin]

    Crane Co. (NYSE: CR) shares were also up, gaining 12 percent to $67.56 on stronger-than-expected Q3 earnings.

    Equities Trading DOWN

  • [By Monica Gerson]

    Crane Co. (NYSE: CR) is expected to post its quarterly earnings at $0.86 per share on revenue of $644.60 million.

    Oceaneering International (NYSE: OII) is projected to post its quarterly earnings at $0.35 per share on revenue of $641.85 million.

Top 10 Gold Stocks To Own Right Now: Applied Materials, Inc.(AMAT)

Advisors’ Opinion:

  • [By Chris Neiger]

    Applied Materials (NASDAQ:AMAT) makes equipment that allows companies to manufacture semiconductors, displays, and other components for some of the most advanced technology on the planet. And just like other tech companies, Applied has to stay ahead of new trends so that it can provide the latest equipment to its customers.

  • [By Craig Jones]

    Pete Najarian spoke on CNBC's "Fast Money Halftime Report" about unusually high bullish options activity in Applied Materials, Inc. (NASDAQ: AMAT).

  • [By Craig Jones]

    On CNBC's "Fast Money Halftime Report", Pete Najarian spoke about a bullish options activity in Applied Materials, Inc. (NASDAQ: AMAT). He noticed that somebody sold 12,000 contracts of the September 42 puts in the first half of the trading session on Tuesday. Najarian explained that the trader believes that the pull back might be over and the stock is close to the bottom.

  • [By Chris Neiger]

    Applied Materials (NASDAQ:AMAT) made investors very happy last year as the company’s stock price rose more than 74%. And that growth has continued into this year, with Applied Materials up more than 10% since the beginning of 2017.

  • [By Chris Lange]

    Short interest in Applied Materials Inc. (NASDAQ: AMAT) rose to 13.95 million shares. The previous reading was 13.21 million. Shares were trading at $38.55, in a 52-week range of $19.46 to $39.81.

  • [By William Patalon III]

    Shares of chip-equipment leader Applied Materials Inc. (Nasdaq: AMAT) have zoomed 80% since we brought them to you in May 2014.

    And they’ve jumped 8% since we re-recommended the stock back on Jan. 31.

Top 10 Gold Stocks To Own Right Now: Sapiens International Corporation N.V.(SPNS)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Trevena Inc (NASDAQ: TRVN) rose 10.8 percent to $3.60 in pre-market trading after dropping 4.97 percent on Wednesday.
    Yum China Holdings Inc (NYSE: YUMC) rose 10.2 percent to $31.05 in pre-market trading after the company reported upbeat earnings for its first quarter.
    Seres Therapeutics Inc (NASDAQ: MCRB) rose 9.1 percent to $11.39 in pre-market trading after dropping 5.26 percent on Wednesday.
    Plug Power Inc (NASDAQ: PLUG) rose 8.9 percent to $2.45 in pre-market trading after surging 73.08 percent on Wednesday.
    Coach Inc (NYSE: COH) rose 6.7 percent to $41.98 in pre-market trading. Coach named Ian Bickley as President, Global Business Development and Strategic Alliances.
    Sapiens International Corporation N.V. (NASDAQ: SPNS) shares rose 6.1 percent to $13.91 in pre-market trading after gaining 0.54 percent on Wednesday.
    Jazz Pharmaceuticals plc (NASDAQ: JAZZ) rose 6.1 percent to $149.15 in pre-market trading. Jazz Pharma reached a settlement with Hikma Pharma related to Xyrem patent case. Mizuho downgraded Jazz from Buy to Neutral.
    Interactive Brokers Group, Inc. (NASDAQ: IBKR) shares rose 6 percent to $36.72 in pre-market trading after declining 0.03 percent on Wednesday.
    Rewalk Robotics Ltd (NASDAQ: RWLK) rose 5.3 percent to $2.00 in pre-market trading after the company disclosed that the U.S. Department of Veterans Affairs purchased 28 added Exoskeleton Systems.
    Merrimack Pharmaceuticals Inc (NASDAQ: MACK) rose 5.1 percent to $3.29 in pre-market trading. Merrimack declared a $1.06 special dividend.
    BioTime, Inc. (NYSE: BTX) shares rose 4.8 percent to $3.50 in pre-market trading. BioTime, reported the formation of new subsidiary AgeX Therapeutics, Inc.
    Akari Therapeutics PLC (ADR) (NASDAQ: AKTX) shares rose 4.8 percent to $12.26 in pre-market trading after gaining 0.69 percent on Wednesday.
    Bed Bath & Beyond Inc. (NASDAQ: BBBY) rose 3.6 percent to $39.15 in pre-market trading after the company posted better-than

Top 10 Gold Stocks To Own Right Now: OncoMed Pharmaceuticals, Inc.(OMED)

Advisors’ Opinion:

  • [By Paul Ausick]

    OncoMed Pharmaceuticals Inc. (NASDAQ: OMED) dropped about 5.3% Wednesday to post a new 52-week low of $4.69 after closing at $4.95 on Tuesday. The stock’s 52-week high is $15.49. Volume was more than double the daily average of around 270,000 shares. The company had no specific news Wednesday.

  • [By Paul Ausick]

    OncoMed Pharmaceuticals Inc. (NASDAQ: OMED) dropped nearly 44% Monday to post a new 52-week low of $4.94 after closing Friday at $8.76. The stock’s 52-week high is $15.49. Volume of about 3.3 million shares was nearly 20 times the daily average of around 182,000. A proposed deal with Bayer AG fell through and one of the company’s drugs failed a phase 2 clinical trial.

  • [By Teresa Rivas]

    OncoMed Pharmaceuticals (OMED) has lost more than a third of its value Monday, after Bayer decided not to exercise its option to license the firms Phase II-ready WNT pathway inhibitors Vantictumab and Ipafricept, which treat pancreatic cancer.

    Pixabay

    That wasnt the only bad news, however, as the firms randomized-controlled Phase II “YOSEMITE” trial of pancreatic cancer drug demcizumab also missed its primary endpoint.

    Leerinks Michael Schmidt and his team reiterated a Market Perform rating on the stock Monday, and lowered their price target from $10 to $6 on the news, calling it a “double setback” for OncoMed.

    More detail from the note:

    This is a major setback for OMED and in our view for the cancer stem cell targets more broadly, which have been a difficult area of drug development. We’ve been cautious on the probability-of-success of these agents and see more promise on OMED’s recent efforts in building a second area of focus in immuno-oncology. Going forward, OMED plans to review and prioritize its R&D pipeline after results from the still pending tarextumab Phase II “PINNACLE” trial in small cell lung cancer (SCLC) and data from the demcizumab “DENALI” trial in NSCLC are available in 2Q17. We remain MP rated in light of the uncertainties around OMED’s pipeline and strategy at this point. We previously assigned a 30% probability of success (POS) to demcizumab which we now have removed from our model. We also think chances that CELG will opt-into this program are slim and we have removed associated POS-adjusted milestone payments from our model. OMED has cash to run operations through 3Q18.

    OncoMed is down 36.1% to $5.60 this afternoon.

Top 10 Gold Stocks To Own Right Now: Deutsche Bank AG(DB)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    Today, Deutsche Bank (DB) pretty much signals an all-clear based on that call and says things are indeed getting better. So there are buyers all over the place.

  • [By Lisa Levin]

    Monday afternoon, the non-cyclical consumer goods & services sector proved to be a source of strength for the market. Leading the sector was strength from Deutsche Bank AG (USA) (NYSE: DB) and Banco Bilbao Vizcaya Argentaria SA (ADR) (NYSE: BBVA).

  • [By Diane Alter]

    The New York Times first reported that Frontier Airlines is prepping for an initial public offering. The Denver, Colo.-based low-cost carrier has hired Deutsch Bank (NYSE: DB), JPMorgan Chase & Co. (NYSE: JPM), and Evercore Partners Inc. (NYSE: EVR) to handle the IPO. The airline started the process late last year when it approached a number of bankers.

Top 10 Gold Stocks To Own Right Now: Columbia Sportswear Company(COLM)

Advisors’ Opinion:

  • [By D.R. Barton, Jr.]

    I bring Mr. Houdini up today because when I look at our favorite “Pop & Drop” play – Columbia Sportswear Co. (Nasdaq: COLM) – I find an eerie similarity to this great “escapesman.”

  • [By Peter Graham]

    A long term performance chart shows mid cap Under Armourpreviously outperforming peers like large cap Nike Inc (NYSE: NKE) and mid cap Columbia Sportswear Company (NASDAQ: COLM), but that outperformance slipped late last year:

  • [By Ben Levisohn]

    Looking at recent historical deals, we arrive at a $18-$23 potential deal range. We analyzed transactions that have been announced over the past four years and involved companies catering to a higher income customer. These deals include Southern Tide (acquired by Oxford Industries (OXM)), Joe’s Jeans (acquired by Sequential Brands Group (SQBG)), prAna (acquired by Columbia Sportswear (COLM)), The Jones Group (acquired by Sycamore Partners [private] and Juicy Couture (acquired by Authentic Brands Group [private]). The average EV/EBITDA multiple of these transactions are 12.9x (in line with KATE’s 5-year historical average of 12.1x) and implies a potential deal range of $22-$23. When taking the average of recent (F13-16) deals implies an ~10.5x EV/EBITDA multiple. When applying the ~10.5x multiples to KATE’s trailing EBITDA, we arrive at an $18- $19 potential share price.

  • [By Matt Hogan]

    SKX is also highly attractive in a relative basis when compared to several of its publicly traded peers: Foot Locker, Inc. (NYSE: FL), Deckers Outdoor Group (NYSE: DECK), Wolverine World Wide, Inc. (NYSE: WWW) and Columbia Sportswear Company (NASDAQ: COLM). The company's forward EBITDA multiple of 6.9x is equal or below all of the comparable companies: FL (6.9x), DECK (7.6x), WWW (10.1x) and COLM (10.8x).

Best Insurance Stocks To Invest In Right Now

31 Worst Paying College Majors: 2017

30 Best Paying College Majors: 2017

Distributions Out of a Cash Value Life Insurance Policy

Labor Secretary Alexander Acosta said Monday that Labor will not delay the fiduciary rule’s June 9 compliance date while the department seeks public input on the rule as laid out in President Donald Trump’s Feb. 3 memorandum.

“The Labor Department has concluded that it is necessary to seek additional public input on the entire fiduciary rule, and we will do so,” Acosta said in a Monday op-ed in The Wall Street Journal.

The RFI will specifically ask for public comment on whether it is likely to take more time to implement these new approaches than what the department envisioned when it set Jan. 1, 2018, as the applicability date for full compliance with all of the exemptions’ conditions, and, if so, whether an additional delay of that date would reduce burdens on financial services providers and benefit retirement investors by allowing for a smoother implementation of those market changes.

Best Insurance Stocks To Invest In Right Now: Shire plc(SHPG)

Advisors’ Opinion:

  • [By Max Macaluso and David Williamson]

    At the end of last week, a Bloomberg article revealed that Shire (NASDAQ: SHPG  ) and pharmaceutical giant Sanofi (NYSE: SNY  ) may be circling ViroPharma (NASDAQ: VPHM  ) . The the following video, from The Motley Fool’s health care show Market Checkup, analysts David Williamson and Max Macaluso take a close look at ViroPharma and discuss the recent interest in this small biotech company.

  • [By Jim Robertson]

    That’s why its worth pointing out that just yesterday, small cap cannabinoid prodrug pharmaceutical stock Vitality Biopharma, Inc. (OTCQB: VBIO) announced the appointment of Tracy Rockney, J.D. to the position of Senior Regulatory Advisor. In addition to being the Co-Founder & Chief Operating Officer of OneSource Regulatory, a regulatory consulting firm, Rockney was previously:

    From May 2010 to May 2015, she was the VP, Regulatory Affairs at AbbVie Inc (NYSE: ABBV) leading the executive functions related to regulatory policy and intelligence. From August 1993 to January 2005, she held positions of increasing responsibility with Pfizer Inc (NYSE: PFE), formerly Wyeth.  From January 2005 to April 2010, she held positions with Shire PLC (NASDAQ: SHPG), including serving as Senior Director, Regulatory Affairs. This included responsibilities as Therapeutic Area Head for Shire’s Gastrointestinal Business Unit, Regulatory Advertising & Promotion and CMC. Rockney led the regulatory team and negotiations with the FDA for LIALDA which are part of the drug class of aminosalicylates that are now part of the clinical standard-of-care for treating inflammatory bowel disease. LIALDA™ was found to be effective in Phase 3 trials for inducing remission of active mild-to-moderate ulcerative colitis after eight weeks of treatment. LIALDA™ (also now marketed as Mezavant®) had 2016 U.S. sales of $714 million – up 16% relative to 2015 sales.

    Rockney’s work for Shire is of particular interest to Vitality Biopharma which has developed a new class of cannabinoid prodrugs (medications or compounds that, after administration, are converted within the body into a pharmacologically active drug), known as cannabosides, which upon ingestion can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Cannabosides could provide therapeutic benefits for infl

  • [By Ben Levisohn]

    We highlight the key takeaways below, which have read-throughs for brand drug companies we cover such asAllergan (AGN), Shire (SHPG), Valeant Pharmaceuticals International, Mallinckrodt,Endo International and Jazz Pharmaceuticals (JAZZ), among others.

  • [By Todd Campbell]

    The partnered portfolio includes Movantik and Adynovate, which are licensed to AstraZeneca (NYSE:AZN) and Shire (NASDAQ:SHPG), respectively.

    Movantik won Food and Drug Administration approval in September 2014 for use in relievingopioid constipation, and Nektar Therapeutics reports that annual prescriptions jumped 270% year over year in 2016. Currently, Movantik is selling at an annualized clip of about $160 million, and according to the licensing agreement, Nektar Therapeutics receives a 20% plus royalty on U.S. sales, plus potential sales milestone payments.

  • [By Ben Levisohn]

    Specialty pharmaceuticals Shire (SHPG) and Mallinckrodt (MNK) soared today following their better-than-expected earnings, while Morgan Stanley worried about Valeant Pharmaceutical International’s (VRX) ability to sell its unwanted assets.

Best Insurance Stocks To Invest In Right Now: BioMarin Pharmaceutical Inc.(BMRN)

Advisors’ Opinion:

  • [By George Budwell, Rich Smith, and Matthew DiLallo]

    With this question in mind, we asked three of our contributors which stocks they recommend to buy and hold for the next 20 years. They suggestedBioMarin Pharmaceutical (NASDAQ:BMRN), Enterprise Products Partners (NYSE:EPD), andLockheed Martin (NYSE:LMT). Below, they discuss why they chose these particular stocks, and why investors with a long-term outlook may want to consider adding them to their portfolios right now.

  • [By Keith Speights]

    You might not have heard too much about Akebia Therapeutics (NASDAQ:AKBA), BioMarin Pharmaceutical (NASDAQ:BMRN), and Idera Pharmaceuticals (NASDAQ:IDRA). These are three biotech stocks that you could be overlooking — but deserve your attention. Here’s why.

  • [By Ben Levisohn]

    Skorney’s namesVertex Pharmaceuticals (VRTX),Sarepta Therapeutics (SRPT), and Curis (CRIS) his top biotech picks for 2017, while Ulz chosesBioMarin Pharmaceutical (BMRN) andParatek Pharmaceuticals (PRTK).

Best Insurance Stocks To Invest In Right Now: OncoMed Pharmaceuticals, Inc.(OMED)

Advisors’ Opinion:

  • [By Teresa Rivas]

    OncoMed Pharmaceuticals (OMED) has lost more than a third of its value Monday, after Bayer decided not to exercise its option to license the firms Phase II-ready WNT pathway inhibitors Vantictumab and Ipafricept, which treat pancreatic cancer.

    Pixabay

    That wasnt the only bad news, however, as the firms randomized-controlled Phase II “YOSEMITE” trial of pancreatic cancer drug demcizumab also missed its primary endpoint.

    Leerinks Michael Schmidt and his team reiterated a Market Perform rating on the stock Monday, and lowered their price target from $10 to $6 on the news, calling it a “double setback” for OncoMed.

    More detail from the note:

    This is a major setback for OMED and in our view for the cancer stem cell targets more broadly, which have been a difficult area of drug development. We’ve been cautious on the probability-of-success of these agents and see more promise on OMED’s recent efforts in building a second area of focus in immuno-oncology. Going forward, OMED plans to review and prioritize its R&D pipeline after results from the still pending tarextumab Phase II “PINNACLE” trial in small cell lung cancer (SCLC) and data from the demcizumab “DENALI” trial in NSCLC are available in 2Q17. We remain MP rated in light of the uncertainties around OMED’s pipeline and strategy at this point. We previously assigned a 30% probability of success (POS) to demcizumab which we now have removed from our model. We also think chances that CELG will opt-into this program are slim and we have removed associated POS-adjusted milestone payments from our model. OMED has cash to run operations through 3Q18.

    OncoMed is down 36.1% to $5.60 this afternoon.

  • [By Paul Ausick]

    OncoMed Pharmaceuticals Inc. (NASDAQ: OMED) dropped nearly 44% Monday to post a new 52-week low of $4.94 after closing Friday at $8.76. The stock’s 52-week high is $15.49. Volume of about 3.3 million shares was nearly 20 times the daily average of around 182,000. A proposed deal with Bayer AG fell through and one of the company’s drugs failed a phase 2 clinical trial.

  • [By Paul Ausick]

    OncoMed Pharmaceuticals Inc. (NASDAQ: OMED) dropped about 5.3% Wednesday to post a new 52-week low of $4.69 after closing at $4.95 on Tuesday. The stock’s 52-week high is $15.49. Volume was more than double the daily average of around 270,000 shares. The company had no specific news Wednesday.